Karyopharm down as FDA reviewers cast doubt on selinexor's benefit

Karyopharm down as FDA reviewers cast doubt on selinexor's benefit

Submitted by admin on February 23, 2019 - 4:35pm
Source: 
BioCentury
News Tags: 
Karyopharm Therapeutics
FDA
Selinexor
Multiple Myeloma
Headline: 
Karyopharm down as FDA reviewers cast doubt on selinexor's benefit
snippet: 

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) lost $3.90 (43%) to $5.07 on Friday after FDA reviewers wrote in briefing documents that it is unclear whether treatment with selinexor provides a clinically meaningful benefit that outweighs the risks of treatment.

Do Not Allow Advertisers to Use My Personal information